Abstract 59P
Background
Although anti-epidermal growth factor receptor (EGFR) therapy has established efficacy in RAS/BRAF wild type (WT) mCRC, 10-20% of WT patients exhibit primary resistance to this treatment. Biomarker discovery has mainly focused on tumor-specific DNA mutations, which suffer from variable mutation frequencies among patients. Epigenetic abnormalities, such as promoter hypermethylation, represent a common and early event in carcinogenesis, making it promising for resistance detection. In fact, several studies have shown an association between DNA methylation patterns and resistance to anti-EGFR therapy in CRC. To validate and build upon these findings, we investigated the methylomes of primary tumors with resistant and responsive phenotypes.
Methods
We isolated DNA from 15 primary CRC tumors. These DNA samples were subjected to Enzymatic Methyl-Sequencing (EMSeq), creating a genome-wide methylation dataset. We calculated methylation levels at CpGs and evaluated their correlation with resistance status. Based on the methylation values, a differential methylation analysis was performed using a modified linear mixed regression model. The CpGs were ranked based on the largest Δmethylation values and most significant p-values across the three patient groups. We performed a false discovery rate (FDR) evaluation, which led to the selection of differentially methylated CpGs (DMCs) with the highest likelihood of being genuine associations. Additionally, the DMCs were used as input for gene set enrichment analysis (GSEA).
Results
The GSEA revealed significant enrichment in 1 KEGG and 8 Reactome pathways, including MAPK-related, Akt and Wnt signaling. A gene ontology (GO) overrepresentation analysis was conducted on the significant genes. Notably, the most prominent GO categories were GTPase activity for molecular function and response to oxidative stress for biological processes.
Conclusions
We have created a comprehensive dataset of methylation sites with a substantial effect on conferring resistance to anti-EGFR therapy in CRC patients. In addition to identifying critical DMCs, the pathways hold potential as a rich source of predictive biomarkers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
University of Antwerp.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract